CYP cynata therapeutics limited

Ann: Proposed issue of securities - CYP, page-12

  1. 4,849 Posts.
    lightbulb Created with Sketch. 344
    "The remarkable capacity of iPSCs to self-renew and differentiate into any cell type makes them a highly versatile tool, but it also means they can accumulate mutations over time, particularly when expanded over extended periods. This introduces the risk of tumourigenesis, where mutations could lead to uncontrolled cell growth and potentially result in cancer."

    https://www.drugtargetreview.com/article/156139/experts-explore-the-future-of-ipsc-based-cell-therapies/

    Do you still want to say that this is not up to date, and the concerns for IPSC treatments by the leading scientists in the world are rubbish?

    Yes it has a future many many years in the future, when it can be proven to be safe.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.5¢
Change
-0.005(2.94%)
Mkt cap ! $37.28M
Open High Low Value Volume
16.5¢ 17.0¢ 16.5¢ $38.44K 230.8K

Buyers (Bids)

No. Vol. Price($)
5 277685 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.0¢ 9872 2
View Market Depth
Last trade - 14.35pm 16/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.